← FDA DRUG APPROVALS

FDA ANDA · ANDA078571

MOMETASONE FUROATE

Sponsor: GLENMARK PHARMS

APPLICATION
ANDA078571
TYPE
ANDA
ORIGINAL APPROVAL
2008-05-28
LATEST ACTION
2024-08-14
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

MOMETASONE FUROATEDiscontinued
MOMETASONE FUROATE 0.1% · OINTMENT · TOPICAL

Approval history

2024-08-14Labeling · Supplement 9 · standardAP
2024-08-14Labeling · Supplement 10 · standardAP
2015-08-18Labeling · Supplement 7 · standardAP
2008-05-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →